In Vivo and In Vitro Pharmacological Studies of Methoxycarbonyl-Carboetomidate | Zendy

Ervin Pejo | Zendy; Joseph F. Cotten | Zendy; Elizabeth Kelly | Zendy; Ri Le Ge | Zendy; Gregory D. Cuny | Zendy; Joydev K. Laha | Zendy; Jifeng Liu | Zendy; Xiang Lin | Zendy; Douglas E. Raines | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vivo and In Vitro Pharmacological Studies of Methoxycarbonyl-Carboetomidate

Author(s) -

Ervin Pejo,

Joseph F. Cotten,

Elizabeth Kelly,

Ri Le Ge,

Gregory D. Cuny,

Joydev K. Laha,

Jifeng Liu,

Xiang Lin,

Douglas E. Raines

Publication year - 2011

Publication title -

anesthesia and analgesia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.404

H-Index - 201

eISSN - 1526-7598

pISSN - 0003-2999

DOI - 10.1213/ane.0b013e3182320559

Subject(s) - etomidate , in vivo , ec50 , pharmacology , chromatography , medicine , chemistry , propofol , in vitro , biochemistry , biology , microbiology and biotechnology

We previously developed 2 etomidate analogs that retain etomidate's favorable hemodynamic properties but whose adrenocortical effects are reduced in duration or magnitude. Methoxycarbonyl (MOC)-etomidate is rapidly metabolized and ultrashort acting whereas (R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (carboetomidate) does not potently inhibit 11β-hydroxylase. We hypothesized that MOC-etomidate's labile ester could be incorporated into carboetomidate to produce a new agent that possesses favorable properties individually found in each agent. We describe the synthesis and pharmacology of MOC-(R)-ethyl 1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (MOC-carboetomidate), a "soft" analog of carboetomidate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research